- North America
- Service category
- Formulation development and drug delivery
Your company? Get access to this profile.
- Antibody services
- Autoimmune disease / inflammation
- Business development
- Drug development
- Licensing / partnering / dealmaking
Zymeworks’ business model leverages its antibody and alternative protein scaffold platforms and focuses on highly-strategic collaborative drug development agreements with pharmaceutical partners and the development of an internal pipeline of antibody and protein-based drug candidates.
Collaborative drug-development agreements with major pharmaceutical companies provide our strategic partners with access to Zymeworks’ platform technologies. Zymeworks remains involved throughout the pre-clinical research and development process to provide tailored molecules with best-in-class characteristics such as half-life, effector function, and stability. Throughout the life of the program Zymeworks benefits from up-front payments, near-term milestone revenue, and long-term royalty streams.
For our internal pipeline, by pursuing a best-in-class development strategy, Zymeworks can mitigate the risk and uncertainty associated with new target discovery and validation. As our internal programs reach meaningful pre- and early clinical inflection points, Zymeworks plans to partner the successful candidates to allow us to continue to exploit our core competencies in protein design and optimization.
You might be also interested in
Sourcing this company's services?Send inquiry anonymously »